StockData
Innoviva, Inc. logo

Innoviva, Inc. (INVA) stock

INVANasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 4, 2026Score 14/3037% below fair value
$18.41+0.00 (0.00%)

Close on Nov 20, 2026Market cap $1.33BP/E 9.3Yield –

Innoviva free cash flow

Free cash flow is cash from operations minus capital expenditures: the cash available for dividends, buybacks, debt repayment or acquisitions.

Innoviva's free cash flow for the twelve months ending Sep 30, 2026 was $182.51M, down 9.0% year over year. For fiscal 2025 it was $195.80M, up 3.9% from the year before. Over ten years it grew 34.5% a year on average. The highest annual figure on record is $363.81M in fiscal 2021.

Annual free cash flow

PeriodPeriod endValueChange
FY2025Dec 31, 2025$195.80M+3.9%
FY2024Dec 31, 2024$188.42M+34.0%
FY2023Dec 31, 2023$140.65M-30.3%
FY2022Dec 31, 2022$201.66M-44.6%
FY2021Dec 31, 2021$363.81M+16.2%
FY2020Dec 31, 2020$313.10M+21.6%
FY2019Dec 31, 2019$257.45M+15.2%
FY2018Dec 31, 2018$223.53M+57.7%
FY2017Dec 31, 2017$141.75M+133.5%
FY2016Dec 31, 2016$60.71M+499.6%
FY2015Dec 31, 2015$10.12M–
FY2014Dec 31, 2014-$131.41M–
FY2013Dec 31, 2013-$132.34M–
FY2012Dec 31, 2012-$130.10M–
FY2011Dec 31, 2011-$91.97M–
FY2010Dec 31, 2010-$76.01M–
FY2009Dec 31, 2009-$58.81M–

Quarterly free cash flow

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q3 FY2026Sep 30, 2026$41.67M-14.3%
Q2 FY2026Jun 30, 2026$51.54M+16.9%
Q1 FY2026Mar 31, 2026$34.79M-28.4%
Q4 FY2025Dec 31, 2025$54.50M-8.0%
Q3 FY2025Sep 30, 2025$48.61M+0.4%
Q2 FY2025Jun 30, 2025$44.07M+0.8%
Q1 FY2025Mar 31, 2025$48.62M+31.2%
Q4 FY2024Dec 31, 2024$59.24M+78.9%
Q3 FY2024Sep 30, 2024$48.42M+10.8%
Q2 FY2024Jun 30, 2024$43.72M+14.5%
Q1 FY2024Mar 31, 2024$37.05M+44.4%
Q4 FY2023Dec 31, 2023$33.11M+273.4%
Q3 FY2023Sep 30, 2023$43.72M+178.8%
Q2 FY2023Jun 30, 2023$38.18M-51.7%
Q1 FY2023Mar 31, 2023$25.65M-73.9%
Q4 FY2022Dec 31, 2022$8.87M-91.0%
Q3 FY2022Sep 30, 2022$15.68M-83.8%
Q2 FY2022Jun 30, 2022$79.02M-6.6%
Q1 FY2022Mar 31, 2022$98.09M+16.6%
Q4 FY2021Dec 31, 2021$98.38M+15.4%
Q3 FY2021Sep 30, 2021$96.71M+29.7%
Q2 FY2021Jun 30, 2021$84.61M+6.0%
Q1 FY2021Mar 31, 2021$84.11M+14.5%
Q4 FY2020Dec 31, 2020$85.28M+27.5%
Q3 FY2020Sep 30, 2020$74.56M+29.9%
Q2 FY2020Jun 30, 2020$79.79M+41.2%
Q1 FY2020Mar 31, 2020$73.47M-4.2%
Q4 FY2019Dec 31, 2019$66.89M+39.8%
Q3 FY2019Sep 30, 2019$57.40M+32.0%
Q2 FY2019Jun 30, 2019$56.50M+168.3%
Q1 FY2019Mar 31, 2019$76.66M–
Q4 FY2017Dec 31, 2017$47.86M–
Q3 FY2017Sep 30, 2017$43.49M–
Q4 FY2016Dec 31, 2016$21.06M–

More Innoviva figures

See a number that looks wrong?